Circulating and extracellular vesicle-associated non-coding RNAs in diabetic retinopathy: a stage-aware framework for network-informed biomarker panels
- 1Medical Course, School of Medicine, Keimyung University
- 2Department of Ophthalmology, Keimyung University School of Medicine
- 3Department of Physiology, Keimyung University School of Medicine
Abstract
Diabetic retinopathy (DR) is a progressive microvascular complication of diabetes in which prognosis and management change substantially across non-proliferative and proliferative stages. Current imaging accurately detects established structural and vascular abnormalities but provides limited insight into early molecular changes or the risk of clinically important transitions within non-proliferative diabetic retinopathy (NPDR). Circulating non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), have emerged as candidate biomarkers because they regulate pathways involved in endothelial dysfunction, inflammation, oxidative stress, and angiogenesis and can be detected in blood and extracellular vesicle (EV)-associated fractions. In this structured narrative review, we synthesize circulating and EV-associated ncRNA evidence within a stage-aware framework aligned with three clinical use cases: early screening, risk stratification within NPDR, and monitoring at the severe NPDR–early proliferative diabetic retinopathy boundary. miRNAs currently provide the most mature evidence for stage-associated expression patterns and, in selected studies, stage-discriminatory performance. By contrast, circulating lncRNA and circRNA evidence remains limited and is predominantly cross-sectional and advanced-stage associated, supporting their use mainly as complementary, network-informing components. EV association may improve RNA stability and enrich disease-relevant signals, but it does not establish retinal origin, and differences in biofluid source, EV isolation and characterization, normalization, and systemic confounders limit cross-study comparability. Importantly, direct evidence for clinically relevant adjacent-stage discrimination and longitudinal prediction remains scarce. We therefore propose that future biomarker development should prioritize stage-aware, network-informed multi-ncRNA panels, standardized pre-analytical and EV workflows, adjustment for major clinical confounders, and longitudinal imaging-integrated validation to determine whether these biomarkers add value beyond conventional retinal staging.
Related
- Evaluating the role of serum cystatin C as a circulating biomarker of diabetic retinopathy from a rural Indian population
- Author’s response to letter of editor for Evaluating the role of serum cystatin C as a circulating biomarker of diabetic retinopathy from a rural Indian population
- Circulating hepatocyte-derived extracellular particles as potential biomarker of steatohepatitis progression to fibrogenesis: Exploring the impact of smoking
- Reduced serum Dickkopf-1 levels as a potential supportive biomarker for the development and severity of retinopathy of prematurity: a prospective observational clinical study
- Minute-Scale Sleep-Onset HRV as a Candidate Risk-Stratification Biomarker for Diabetic Retinopathy: An Exploratory Pilot Study
BibTeX
@article{yu2026circulating,
title = {{Circulating and extracellular vesicle-associated non-coding RNAs in diabetic retinopathy: a stage-aware framework for network-informed biomarker panels}},
author = {Ji-Won Yu and Myung-Ji Choi and Dong Cheol Lee and Jae-Hyung Park},
journal = {Frontiers in Endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1970838},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1970838/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Circulating and extracellular vesicle-associated non-coding RNAs in diabetic retinopathy: a stage-aware framework for network-informed biomarker panels
AU - Ji-Won Yu
AU - Myung-Ji Choi
AU - Dong Cheol Lee
AU - Jae-Hyung Park
PY - 2026
DA - 2026/10/21
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1970838
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1970838/full
AB - Diabetic retinopathy (DR) is a progressive microvascular complication of diabetes in which prognosis and management change substantially across non-proliferative and proliferative stages. Current imaging accurately detects established structural and vascular abnormalities but provides limited insight into early molecular changes or the risk of clinically important transitions within non-proliferative diabetic retinopathy (NPDR). Circulating non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), have emerged as candidate biomarkers because they regulate pathways involved in endothelial dysfunction, inflammation, oxidative stress, and angiogenesis and can be detected in blood and extracellular vesicle (EV)-associated fractions. In this structured narrative review, we synthesize circulating and EV-associated ncRNA evidence within a stage-aware framework aligned with three clinical use cases: early screening, risk stratification within NPDR, and monitoring at the severe NPDR–early proliferative diabetic retinopathy boundary. miRNAs currently provide the most mature evidence for stage-associated expression patterns and, in selected studies, stage-discriminatory performance. By contrast, circulating lncRNA and circRNA evidence remains limited and is predominantly cross-sectional and advanced-stage associated, supporting their use mainly as complementary, network-informing components. EV association may improve RNA stability and enrich disease-relevant signals, but it does not establish retinal origin, and differences in biofluid source, EV isolation and characterization, normalization, and systemic confounders limit cross-study comparability. Importantly, direct evidence for clinically relevant adjacent-stage discrimination and longitudinal prediction remains scarce. We therefore propose that future biomarker development should prioritize stage-aware, network-informed multi-ncRNA panels, standardized pre-analytical and EV workflows, adjustment for major clinical confounders, and longitudinal imaging-integrated validation to determine whether these biomarkers add value beyond conventional retinal staging.
SN - 1664-2392
ER -